[go: up one dir, main page]

WO2011114346A1 - Chitine et composés apparentés destinés à être utilisés dans le traitement d'infections bactériennes et virales - Google Patents

Chitine et composés apparentés destinés à être utilisés dans le traitement d'infections bactériennes et virales Download PDF

Info

Publication number
WO2011114346A1
WO2011114346A1 PCT/IN2010/000605 IN2010000605W WO2011114346A1 WO 2011114346 A1 WO2011114346 A1 WO 2011114346A1 IN 2010000605 W IN2010000605 W IN 2010000605W WO 2011114346 A1 WO2011114346 A1 WO 2011114346A1
Authority
WO
WIPO (PCT)
Prior art keywords
flu
efficient treatment
recited
chitin
seasonal flu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000605
Other languages
English (en)
Inventor
Chetan Balar
Anil Nakum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011114346A1 publication Critical patent/WO2011114346A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • FIELD OF INVENTION This invention is based on treatment of seasonal flu which is caused by bacterial as well as viral species especially swine flu and all influenza A, B, & C viruses.
  • the dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response.
  • the dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein.
  • the enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.
  • the present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers.
  • the invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples 5 including diagnostic and prognostic methods.
  • MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactiyation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.
  • the invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc.
  • the invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.
  • 5' phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL- 1 ⁇ production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, rum, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
  • Single- stranded 5' triphosphate RNA can be used for inducing an anti-viral response, an anti- bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL- 1 ⁇ production, in a target cell-specific manner.
  • WO 2010/009735 A2 (patent application) wherein A method for the repair of a unit, by specific diagnosis of the undesired state, and its appropriate repair, using said specific diagnosis as a means to repair in an appropriate way said unit.
  • the diagnosis and repair processes may involve chemical, physical, or mechanical means.
  • the units being diagnosed and repaired include live matter (e.g. human beings, animals, plants) as well as non-live matter (e.g. buildings, electronic equipment, polymer materials).
  • Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed.
  • the compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods.
  • novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed.
  • the possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis.
  • the invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
  • the present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences.
  • the vaccine stimulates an immune response, especially an immune response in an MHC-I dependent, but CD4 + T-cell independent manner
  • the invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus.
  • the invention also provides peptide epitopes 5 for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza
  • compositions comprising one or more influenza antigens, one or more detoxified ADP-ribosylating proteins, and one or more chitosans.
  • the invention also relates to methods of using these compositions to generate an immune response to influenza.
  • the main object of the invention is to introduce the use of natural compound chitin for the treatment of both the seasonal flu which is caused by respiratory bacteria species, and for the treatment of respiratory viral flu. Till date there is no single product which can be used for treatment of both seasonal flu (caused by bacteria) as well as viral flu (caused by virus). Chitin is totally harmless, cost effective and easily available as compared to other products like various flu drugs and vaccine which are not only expensive but are also associated with side effects as they are manufactured industrially by chemical processing. Chitin is very effective natural compound for giving protection against flu bacterial and viruses and also effectively applicable for the treatment of flu resulting from viruses (especially airborne) and respiratory pathogens including swine flu virus (H1N1 novel- 2009).
  • This invention is based on efficient treatment of seasonal flu which is caused by respiratory viral flu especially swine flu and all influenza A, B, & C viruses and respiratory bacterial species like Streptococci, H Influenza, Klebciella pneumonia, S. aureus, Pseudomonas, E.coli, Corenybacterium dipthariae, MTB thereof
  • This invention is based on medicinal use of natural compound chitin for seasonal flu which is caused by respiratory bacteria species as well as respiratory viral flu caused by virus. Chitin is also helpful in prophylaxis of any respiratory infection.
  • the main advantage of this compound is that it is useful for the treatment of swine flu like Influenza viruses (H1N1) and all influenza A, B, & C viruses. It's also useful for the treatment of following bacteria spices like Streptococci, H Influenza, Klebciella pneumonia, S. aureus, Pseudomonas, E.coli, Corenybacterium dipthariae, MTB thereof.
  • CHITIN- It is natural polysaccharide, water soluble, hypoallergic and non toxic to human body in compare to other toxic drugs.
  • Chitin in special concentration i.e. at particulate size ⁇ 10 ⁇ and even in soluble form when administered intranasal or in oral spray form increases NK Cells activity, Macrophage activity as well as increases the level of IL-1B, IL-6, IL-10, IL-12, IL-18, INF- ⁇ , TNF-a and Th 1 type Cytokines. Ultimately it activates Mucosal Innate Immunity and prevents pathogens from establishing infection and even severity of the disease also gets lowered down when it is administered.
  • H IN 1 type virus the increased level of IL- 18, NK CELLs in conjunction with various Cytokines and INFs, TNFs, and, CD Helper Cells limits infection to upper respiratory tract and thereby reducing the intensity of virus attack.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le traitement de la grippe saisonnière qui est provoquée par des espèces de bactéries telles que Streptococci, H Influenza, Klebciella pneumonia, S. aureus, Pseudomonas, E.coli, Corenybacterium dipthariae, leur MTB et des espèces virales comme les virus de la grippe (HlNl) et tous les virus A, B, et C de la grippe, spécifiquement la grippe porcine. La chitine et les dérivés de chitine (comme la D-glucosamine, le chitosane) lorsqu'ils sont administrés par voie intranasale ou sous forme d'un pulvérisateur buccal suivant une concentration spécifique par exemple avec une granulométrie < 10 μm augmentent l'activité des cellules NK, l'activité macrophage et accroissent également le taux de IL-IB, IL-6, IL-IO, IL-12, IL-18, INF-γ, TNF-α et des cytokines du type Th 1. En dernier lieu, ils activent l'immunité innée mucosale et empêchent les pathogènes d'établir l'infection et réduisent par conséquent la gravité de la maladie. Pour le traitement du virus HlNl, la présence de chitine augmente le niveau et l'activité de IL-18, de cellules NK en liaison avec diverses cytokines et INF, TNF, et cellules assistantes CD qui limitent l'infection aux voies respiratoires supérieures et réduisent par conséquent l'intensité de l'attaque virale.
PCT/IN2010/000605 2010-03-18 2010-09-13 Chitine et composés apparentés destinés à être utilisés dans le traitement d'infections bactériennes et virales Ceased WO2011114346A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN710/MUM/2010 2010-03-18
IN710MU2010 2010-03-18

Publications (1)

Publication Number Publication Date
WO2011114346A1 true WO2011114346A1 (fr) 2011-09-22

Family

ID=43759624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000605 Ceased WO2011114346A1 (fr) 2010-03-18 2010-09-13 Chitine et composés apparentés destinés à être utilisés dans le traitement d'infections bactériennes et virales

Country Status (1)

Country Link
WO (1) WO2011114346A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520755A (ja) * 2012-05-18 2015-07-23 ウニヴェルスィテット ヤギエルロンスキ コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用
WO2022125012A1 (fr) * 2020-12-11 2022-06-16 Cukurova Universitesi Rektorlugu Conjugants de glucosamine-acide férulique utilisés en tant que nouveaux ingrédients d'agent anti-viral

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183556A2 (fr) * 1984-11-29 1986-06-04 IHARA CHEMICAL INDUSTRY Co., Ltd. Utilisation d'oligomères de chitine ou chitosane pour la fabrication d'un agent augmentant l'immunité contre les infections bactérielles et mycotiques et contre la croissance de tumeurs
AU2004230485A1 (en) 2003-04-10 2004-10-28 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus
CN1548056A (zh) * 2003-05-08 2004-11-24 天津市金士力药物研究开发有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
US20050255121A1 (en) 2003-05-12 2005-11-17 Campbell Robert L Molecules enhancing dermal delivery of influenza vaccines
WO2007062656A2 (fr) 2005-11-30 2007-06-07 Copenhagen University Vaccin nucléotidique
WO2008017473A2 (fr) 2006-08-08 2008-02-14 Gunther Hartmann Structure et utilisation d'oligonucléotides 5'-phosphate
AU2007310753A1 (en) 2006-10-26 2008-05-02 Glykos Finland Oy Peptide vaccine for influenza virus
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
EP1594536B1 (fr) 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Vaccin contre la grippe contenant un adjuvant
WO2009106073A2 (fr) 2008-02-28 2009-09-03 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183556A2 (fr) * 1984-11-29 1986-06-04 IHARA CHEMICAL INDUSTRY Co., Ltd. Utilisation d'oligomères de chitine ou chitosane pour la fabrication d'un agent augmentant l'immunité contre les infections bactérielles et mycotiques et contre la croissance de tumeurs
EP1594536B1 (fr) 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Vaccin contre la grippe contenant un adjuvant
AU2004230485A1 (en) 2003-04-10 2004-10-28 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
AU2004230485B2 (en) 2003-04-10 2009-01-22 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus
CN1548056A (zh) * 2003-05-08 2004-11-24 天津市金士力药物研究开发有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
US20050255121A1 (en) 2003-05-12 2005-11-17 Campbell Robert L Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
WO2007062656A2 (fr) 2005-11-30 2007-06-07 Copenhagen University Vaccin nucléotidique
WO2008017473A2 (fr) 2006-08-08 2008-02-14 Gunther Hartmann Structure et utilisation d'oligonucléotides 5'-phosphate
WO2008049974A2 (fr) 2006-10-26 2008-05-02 Glykos Finland Oy Vaccin peptidique contre le virus de la grippe
AU2007310753A1 (en) 2006-10-26 2008-05-02 Glykos Finland Oy Peptide vaccine for influenza virus
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
WO2009106073A2 (fr) 2008-02-28 2009-09-03 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ICHINOHE TAKESHI ET AL: "Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.", JOURNAL OF MEDICAL VIROLOGY JUN 2007 LNKD- PUBMED:17457919, vol. 79, no. 6, June 2007 (2007-06-01), pages 811 - 819, XP002630268, ISSN: 0146-6615 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520755A (ja) * 2012-05-18 2015-07-23 ウニヴェルスィテット ヤギエルロンスキ コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用
WO2022125012A1 (fr) * 2020-12-11 2022-06-16 Cukurova Universitesi Rektorlugu Conjugants de glucosamine-acide férulique utilisés en tant que nouveaux ingrédients d'agent anti-viral

Similar Documents

Publication Publication Date Title
Safarzadeh et al. Chitin and chitosan as tools to combat COVID-19: A triple approach
Zheng et al. Intranasal administration of chitosan against influenza A (H7N9) virus infection in a mouse model
CA2674042C (fr) Agents immunostimulants non specifiques
Skhodova et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors
Chan et al. Review of influenza virus vaccines: the qualitative nature of immune responses to infection and vaccination is a critical consideration
Ivanov et al. Inflammasomes as targets for adjuvants
Gutjahr et al. New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
EP3403671B1 (fr) Vaccin contenant des particules virales immobilisées
Tateishi et al. CpG ODN G9. 1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses
Raj et al. Determining the protective efficacy of Toll-like receptor ligands to minimize H9N2 avian influenza virus transmission in chickens
Kayesh et al. Recent insights into the molecular mechanisms of the toll-like receptor response to influenza virus infection
Cheng et al. Inhibition of influenza virus infection with chitosan–sialyloligosaccharides ionic complex
JP2012504948A5 (fr)
Yang et al. The immunogenicity of Alum+ CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
Hua et al. Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice
WO2011114346A1 (fr) Chitine et composés apparentés destinés à être utilisés dans le traitement d&#39;infections bactériennes et virales
JP2013506682A (ja) 異種亜型インフルエンザｔ細胞応答を誘発するためのペプチド
Abdulaziz et al. Evaluation of the Immuno-Responses to Brucella Melitensis.
Sadati et al. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model
Mifsud et al. Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR‐2 agonist Pam2Cys
Kim et al. Vaccination of rock bream, Oplegnathus fasciatus (Temminck & Schlegel), using a recombinant major capsid protein of fish iridovirus.
EA024010B1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
Noh et al. Programming of influenza vaccine broadness and persistence by mucoadhesive polymer-based adjuvant systems
US20240148864A1 (en) Polysaccharide adjuvants for virus vaccines
EP4295861A1 (fr) Nouveau traitement et prévention basés sur une nouvelle méthode de régulation de l&#39;immunité cellulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805840

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10805840

Country of ref document: EP

Kind code of ref document: A1